Organogenesis (NASDAQ:ORGO) Trading Up 9.5% – Should You Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO)’s stock price was up 9.5% during mid-day trading on Monday . The company traded as high as $5.22 and last traded at $5.35. Approximately 713,477 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 1,084,962 shares. The stock had previously closed at $4.88.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Stock Down 10.0 %

The firm’s 50 day simple moving average is $4.13 and its two-hundred day simple moving average is $3.55. The firm has a market cap of $596.09 million, a price-to-earnings ratio of -78.33 and a beta of 1.66. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the transaction, the director now owns 166,879 shares in the company, valued at $851,082.90. The trade was a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 36.90% of the company’s stock.

Institutional Trading of Organogenesis

Large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its stake in Organogenesis by 16.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 39,159 shares of the company’s stock valued at $125,000 after purchasing an additional 5,551 shares during the last quarter. Millennium Management LLC raised its position in Organogenesis by 2.8% in the fourth quarter. Millennium Management LLC now owns 208,420 shares of the company’s stock worth $667,000 after acquiring an additional 5,765 shares during the period. ProShare Advisors LLC raised its holdings in shares of Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after purchasing an additional 6,689 shares during the period. Rhumbline Advisers lifted its position in shares of Organogenesis by 7.1% during the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company’s stock valued at $369,000 after buying an additional 7,621 shares during the last quarter. Finally, State Street Corp boosted its position in Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares during the period. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.